ESPR Stock Overview
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C).
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Esperion Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.99 |
| 52 Week High | US$3.40 |
| 52 Week Low | US$0.70 |
| Beta | 0.82 |
| 1 Month Change | -26.30% |
| 3 Month Change | -6.57% |
| 1 Year Change | 59.20% |
| 3 Year Change | -92.71% |
| 5 Year Change | -95.34% |
| Change since IPO | -86.28% |
Recent News & Updates
Recent updates
A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics
Feb 28Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations
Jan 22Esperion Is Sitting On A Potential Blockbuster Drug
Jan 14Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Jun 19
Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts
Mar 09Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%
Feb 23Esperion says Nexletol recommended as oral non-statin therapy for lowering cholesterol
Aug 26Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings
Aug 09Esperion Therapeutics Q2 2022 Earnings Preview
Aug 01Esperion Therapeutics: 2021 Labors Paying Off In 2022
May 07Esperion Therapeutics: Ready For Growth Ahead Of Clear Outcomes Topline Data Readout
Feb 24Esperion Therapeutics: A Potential 'Bio Boom' Or Bust In 2022
Jan 20Esperion: Bullish On Cost-Cutting Ahead Of Expected Demand Inflection
Oct 27Esperion: Hunting Big Game In The Danger Zone
Aug 05Esperion Therapeutics, Inc. (NASDAQ:ESPR) Analysts Are Reducing Their Forecasts For This Year
May 09Esperion Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 04Shareholder Returns
| ESPR | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 6.4% | -0.6% | 1.0% |
| 1Y | 59.2% | 10.6% | 21.9% |
Return vs Industry: ESPR exceeded the US Pharmaceuticals industry which returned 13.2% over the past year.
Return vs Market: ESPR exceeded the US Market which returned 24.9% over the past year.
Price Volatility
| ESPR volatility | |
|---|---|
| ESPR Average Weekly Movement | 12.1% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ESPR's share price has been volatile over the past 3 months.
Volatility Over Time: ESPR's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 240 | Sheldon Koenig | www.esperion.com |
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company’s products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C.
Esperion Therapeutics, Inc. Fundamentals Summary
| ESPR fundamental statistics | |
|---|---|
| Market cap | US$376.91m |
| Earnings (TTM) | -US$209.25m |
| Revenue (TTM) | US$116.33m |
3.2x
P/S Ratio-1.8x
P/E RatioIs ESPR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ESPR income statement (TTM) | |
|---|---|
| Revenue | US$116.33m |
| Cost of Revenue | US$129.37m |
| Gross Profit | -US$13.04m |
| Other Expenses | US$196.21m |
| Earnings | -US$209.25m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | -1.10 |
| Gross Margin | -11.21% |
| Net Profit Margin | -179.87% |
| Debt/Equity Ratio | -117.9% |
How did ESPR perform over the long term?
See historical performance and comparison